Clinical Trials
12 trialsNCT06904066 2026-05-27
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07572006 2026-05-26
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07257419 2026-05-19
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT02862275 2026-05-13
Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03816345 2026-05-13
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT03399799 2026-05-08
MonumenTAL-1
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06870487 2026-05-08
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Phase 1 Terminated
NCT05849207 2026-05-07
GeriBMT
Cedars-Sinai Medical Center
Phase 1 Recruiting
NCT05887167 2026-05-07
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Cedars-Sinai Medical Center
Phase 1 Recruiting
NCT03560882 2026-05-06
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
University of Kansas Medical Center
Phase 1 Active not recruiting
NCT04771572 2026-05-05
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
Phase 1 Recruiting
NCT07195916 2026-05-04
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
Phase 1 Recruiting